8-K: Scorpius Holdings Extends Debt Maturity, Secures Loan with Asset Lien and Implements 1-for-200 Reverse Stock Split

Scorpius Holdings has amended a promissory note, extending its maturity date and securing it with a subordinated lien on company assets, while also implementing a 1-for-200 reverse stock split to regain compliance with NYSE American listing requirements.

Summary

• Scorpius Holdings amended a promissory note with Elusys Holdings, extending the maturity date to July 31, 2024.
• The note is now secured by a subordinated lien on Scorpius' assets, meaning it's secondary to any future secured financing.
• The company's stockholders approved a 1-for-200 reverse stock split, which was implemented on July 17, 2024.
• The reverse stock split reduced the number of outstanding shares from 98,827,831 to approximately 494,138.
• Fractional shares resulting from the split will be paid out in cash based on the average closing price of the stock over the ten days preceding July 17, 2024.
• The company also increased the number of shares available under its 2018 Stock Incentive Plan by 30,000,000 shares, bringing the total to 38,857,141 shares.
• The company's stock will trade under the temporary ticker symbol 'SCPX' on the OTC Markets starting July 18, 2024, before reverting to 'SCPX' after 20 business days.

Sentiment

Score: 4

Explanation: The document contains a mix of positive and negative developments. The extension of the debt maturity is positive, but the reverse stock split and temporary move to the OTC markets are negative indicators. The overall sentiment is cautiously negative due to the company's need to regain compliance with the NYSE American.

Positives

• The extension of the promissory note provides the company with additional time to repay the debt.
• Securing the note with a lien on assets may provide the lender with more confidence in the company's ability to repay.
• The reverse stock split aims to increase the stock price to regain compliance with NYSE American listing requirements.

Negatives

• The promissory note is secured by a subordinated lien, meaning it is lower priority than other secured debt.
• The reverse stock split reduces the number of outstanding shares, which can be perceived negatively by some investors.
• The company's stock will temporarily trade on the OTC Markets, which is generally considered a less prestigious exchange than the NYSE American.

Risks

• There is no guarantee that the reverse stock split will increase the stock price sufficiently to meet NYSE American listing requirements.
• The company's ability to raise capital and sustain operations is dependent on its cash balance and ability to secure financing.
• The company faces regulatory risks and limitations that could impact its ability to promote its services and compete effectively.

Future Outlook

The company is focused on regaining compliance with NYSE American listing requirements and continuing to develop and manufacture biologics and cell therapies. The company's ability to achieve long-term profitability is dependent on its ability to leverage fixed costs and obtain regulatory approvals.

Management Comments

• The company's board of directors approved a 1-for-200 reverse stock split to increase the selling price of the company's common stock in order to regain compliance with the requirements and policies of the NYSE American.
• The company is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing.

Industry Context

The company operates in the contract development and manufacturing organization (CDMO) sector, which is experiencing growth due to the increasing demand for outsourced services in the pharmaceutical and biotech industries. The reverse stock split is a common strategy for companies facing delisting from major exchanges.

Comparison to Industry Standards

• Reverse stock splits are a common tactic for companies facing delisting from major exchanges, such as the NYSE American, to increase their share price and meet minimum listing requirements. Companies like Sorrento Therapeutics and Cassava Sciences have also recently undertaken reverse stock splits.
• The increase in shares available under the stock incentive plan is a common practice to attract and retain talent in the competitive biotech industry. Many companies in the sector, such as Amgen and Regeneron, have similar stock incentive plans.
• The use of a subordinated security interest is a common practice in debt financing, where lenders prioritize their claims based on risk assessment. This is similar to how many smaller biotech companies structure their debt.

Related Party Transactions

• The promissory note was issued to Elusys Holdings Inc., a company controlled by Scorpius' Chairman, Chief Executive Officer, and President, Jeffrey Wolf.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own due to the reverse stock split, but their ownership percentage will remain the same, except for fractional shares.
• Employees may be impacted by the changes in the stock incentive plan.
• Creditors may be impacted by the subordinated security interest granted to Elusys Holdings.

Next Steps

• The company will need to successfully appeal the determination to the Exchanges Listing Qualifications Panel to have its Common Stock remain listed and recommence trading on the NYSE American.
• The company will need to manage its cash balance and potentially raise capital to sustain operations.
• The company will need to continue to seek regulatory approvals and comply with ongoing regulatory requirements.

Key Dates

Keywords

reverse stock split, promissory note, debt financing, security interest, NYSE American, stock incentive plan, Elusys Holdings, Scorpius Holdings, OTC Markets